<DOC>
	<DOCNO>NCT01831687</DOCNO>
	<brief_summary>This open Label , balance , randomize , single dose , two-treatment , two-sequence , two-period , crossover , oral pivotal bioequivalence study . The purpose study assess bioequivalence Test Product correspond Reference Product fed condition healthy , adult human subject .</brief_summary>
	<brief_title>Bioequivalence Study Etodolac Extended Release Tablets USP 600mg Under Fed Condition</brief_title>
	<detailed_description>Objective pivotal study assess bioequivalence Test Product : Etodolac Extended Release Tablets USP 600mg Ipca Laboratories Limited , India correspond Reference Product : Etodolac Extended Release Tablets 600 mg Teva Pharmaceutical Ind . Ltd. , USA fed condition healthy , adult , human subject randomize crossover study . The study conduct 36 healthy adult subject . In study period , single 600 mg dose either test reference administer subject per randomization schedule study period 240 mL water ambient temperature sit position . The duration clinical phase approximately 15 day include washout period 11 day administration study drug study period .</detailed_description>
	<mesh_term>Etodolac</mesh_term>
	<criteria>Healthy male nonpregnant female subject ( age range 18 45 year ) . Body Mass Index ( 18.5 24.9 kg/m2 ) minimum 50 kg weight . Subjects normal health determine personal medical medication history , clinical examination laboratory examination within clinically acceptable reference range . Subjects normal 12lead electrocardiogram ( ECG ) normal chest XRay ( P/A view ) . Subjects negative urine screen drug abuse ( include amphetamine , barbiturate , benzodiazepine , marijuana , cocaine , morphine ) . Subjects negative alcohol breath test . Subjects willing adhere protocol requirement provide write informed consent . Subjects negative betahCG Pregnancy test ( female subject ) . For Female Subjects : Female child bear potential practicing acceptable method birth control duration study judge investigator ( ) , condom , foam , jelly , diaphragm , intrauterine device ( IUD ) , abstinence , Postmenopausal least 1 year , less 1 year , follow acceptable contraceptive measure mention Surgically sterile ( bilateral tubal ligation , bilateral oophorectomy , hysterectomy perform subject ) . Hypersensitivity Etodolac related class drug . History presence significant cardiovascular , pulmonary , hepatic , renal , gastrointestinal , endocrine , immunological , dermatological , neurological psychiatric disease disorder . History presence significant alcoholism drug abuse . History presence significant smoking . History presence significant asthma , urticaria allergic reaction . History presence significant gastric and/or duodenal ulceration . History presence significant thyroid disease , adrenal dysfunction , organic intracranial lesion pituitary tumor . History presence cancer . Difficulty donate blood . Difficulty swallow solid like tablet capsule . Use prescribed medication OTC medical product last two week prior dose period 01 . Major illness 3 month screen . Participation drug research study within past 3 month . Donation blood past 3 month screen . Consumption grapefruit juice , xanthinecontaining product , tobacco containing product alcohol within 48 hour prior dose . Positive screen test one : HIV , Hepatitis B Hepatitis C. History presence significant easy bruise bleeding . History presence significant recent trauma . Subjects abnormal diet ( whatever reason ) four week precede study . Female subject currently breast feeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>